References
- Adler G., Mullenhoff A., Koop I., Bozkurt T., Goke B., Beglinger C., Arnold R. Stimulation of pancreatic secretion in man by a protease inhibitor (camostate). European Journal of Clinical Investigation 1988; 18: 98–104
- Beckh K., Goke B., Muller R., Arnold R. Elimination of the low-molecular weight proteinase inhibitor camostate (FOY-305) and its degradation products by the rat liver. Research in Experimental Medicine 1987; 187: 401–406, Berlin
- Dobrinska M. R. Enterohepatic circulation of drugs. Journal of Clinical Pharmacology 1989; 29: 577–580
- Forrest T. J., Taylor T., Chasseaud L. F., Irons S. R., Salmon P. F., Bonn R. Tolerance and pharmacokinetics of camostat mesylate (FOY-305) in normal human subjects after single rising i.v. infusion doses. European Journal of Clinical Pharmacology 1989; 36, Suppl. Abstracts of the Fourth World Conference on Clinical Pharmacology and Therapeutics, Mannheim-Heidelberg, Germany, July 1989
- Gibaldi M., Perrier D. Pharmacokinetics2nd Edn. Marcel Dekker, New York 1982
- Hiraku S., Muryobayashi K., Ito H., Inagawa T., Tsuboshima M. Absorption and excretion of camostat (FOY-305) oraily administered to male rabbit and healthy subject. Iyakuhin Kenkyu 1982; 13: 756–765
- Kayama N., Sakaguchi K., Fujii S. Protease inhibitory effects of FOY-305 (I): biochemical studies in vivo. Gendai-Iryo 1980a; 12: 1–10
- Kayama N., Sakaguchi K., Kaneko S., Fujii S. Protease inhibitory effects of FOY-305 (II): from in vitro to in vivo studies. Gendai-Iryo 1980b; 12: 11–18
- Kitagawa M., Hayakawa T., Kondo T., Shibata T., Sugitomo Y. Pancreatic and biliary excretion of camostat in dogs. Digestion 1988; 39: 204–209
- Midgley I., Hawkins D. R., Chasseaud L. F. The metabolic fate of the antidepressive agent amitryptyline N-oxide in man. Arzneimittel-Forschung 1978; 28: 1911–1916
- Nishihata T., Saitoh Y., Sakai K. Intestinal absorption of N,N-dimethylcarbamoylmethyl 4-(4-guanidinobenzoyloxy)phenylacetate methanesulphonate in rats. Chemical and Pharmaceutical Bulletin 1988; 36: 2544–2550, (Tokyo)
- Ohki S., Nishiyama H., Ozeki K., Ito H., Hirata F. Studies on absorption, distribution, metabolism and excretion of [14C]FOY-305. Gendai-Iryo 1980; 12: 71–82
- Øie S., Tozer T. Effect of altered protein binding on apparent volume of distribution. Journal of Pharmaceutical Sciences 1979; 68: 1203–1205
- Rowland M., Tozer T. Clinical Pharmacokinetics Concepts and Applications2nd Edn. Lea & Febiger, Philadelphia 1989; 446
- Smith R. L. The Excretory Function of Bile. Chapman & Hall, London 1973
- Takasugi S., Yonezawa H., Ikei N., Kanno T. Prevention of acute experimental pancreatitis in rats and dogs by intraduodenal infusion of a synthetic trypsin inhibitor. Digestion 1982; 24: 36–41
- Tanaka N., Tsuchiya R., Ishii K. Comparative clinical study of FOY and trasylol. Advances in Experimental Medicine and Biology 1979; 120B: 367–378